Reviews Estradiol, Levonorgestrel Transdermal


No reviews yet.

Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009





Other reviews about Estradiol, Levonorgestrel Transdermal on wordpress

Tramadol Macrophage wall antibiotics water
  by joyaneharpern
. Clinical trials involving 755 US women confirmed that Levlite provides high contraceptive efficacy with good cycle control. Condoms are favored by 33% of unmarried women and 19% […]


FDA Approved Bioidentical Hormones
  by bodylogicmd
We've mentioned that the FDA has approved over 20 bioidentical hormones and now want to share some of the hormones on that list, specifically those meant to treat […]


Buy Hormones
  by Claire
  HRT -  Transgender Hormone Replacement Therapy   *For full details and risks associated with HRT please consult your doctor before taking. NO PRESCRIPTION REQUIRED NO RX CERTIFICATE NEEDED Importation: Importation of […]


Ortho Evra and Venous Thromboembolism Risk – Why You Need to Read More Than Abstracts
  by Nicholas Fogelson
When Ortho Evra, the contraceptive patch came on the market, physicians were happy that women had a new and novel contraceptive method that significantly expanded options over what […]


anabol testosterone and anobol
  by nanonutricals
Testosterone is a steroid hormone from the androgen group. In mammals, testosterone is primarily secreted in the testes of males and the ovaries of females, although small amounts […]


Im just as glad to have him home.
  by uxeexesnsptka
An Inuit does not waste a good dog on his son till the boy knows something of dogdriving; and Kotuko was more than sure that he knew more […]


He staggered to his f
  by ximynuphgxpm
Oppression sat heavily upon them; the lightness of their natures had ebbed out of them; they were slack and absentminded in their service, and they whispered gloomily to […]


The upper end of the pole fell down.
  by vvdgdsxzxz
Its our hobby, and it may really be useful some day. Lubbock sat four hours watching. ] [Sidenote: Caesars increasing popularity. Mail oder steroids Sodium lauryl sulfates allergy Helping combat […]


With the roast in the oven, she wen
  by vnqtocbyjdvnv
Take care he dont hear you, sir, or you may be sorry for it. Farrell smiled a little and was silent. And Felicity, much to our […]


At ten oclock her paper was covered with
  by vkokieuddibox
Homers world, restricted to less than a drummers circuit, was nevertheless immense, surrounded by a thin veneer of universethe Stream of Ocean. Pray, restrain your lively tongue, for […]



Other reviews about Estradiol, Levonorgestrel Transdermal on web:

Consumer information about the medication ESTRADIOL/LEVONORGESTREL WEEKLY - TRANSDERMAL (Climara Pro), includes side effects, drug interactions, recommended dosages, and storage ... ESTRADIOL/LEVONORGESTREL WEEKLY - TRANSDERMAL (Climara Pro) side ...


Estradiol, Levonorgestrel Transdermal patch - weekly To return to the main entry click here . What is this medicine? ESTRADIOL; LEVONORGESTREL (es tra Estradiol, Levonorgestrel Transdermal patch - weekly: Information ...


Estradiol/levonorgestrel(transdermal) (patch, Extended Release)Climara Pro Estradiol/levonorgestrel(transdermal) (patch, Extended Release ...


Estradiol, Levonorgestrel Transdermal patch - weekly What is this medicine? ESTRADIOL; LEVONORGESTREL (es tra DYE ole; LEE voh nor jes trel) is used as hormone replacement in ... Estradiol; Levonorgestrel


Estradiol, Levonorgestrel Transdermal patch - weekly Estradiol; Levonorgestrel


NOW AVAILABLE Black Box Warnings Study Guide A complete printed copy of all Black Box Warning information. The 2010 edition will contain all warning data up to April 1, 2010. Estradiol/Levonorgestrel (Transdermal) - BlackBoxRX.com


Climarapro (Estradiol / Levonorgestrel Transdermal) - Drug Info, Side Effects, Research, Clinical Trials Climarapro (Estradiol / Levonorgestrel Transdermal) - Drug Info ...


Learn about the prescription medication Climara Pro (Estradiol, Levonorgestrel Transdermal), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Climara Pro (Estradiol, Levonorgestrel Transdermal) Drug ...


The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment. $57.95 plus tax ... IngentaConnect 17beta-Estradiol/Levonorgestrel Transdermal System


Estradiol, Levonorgestrel Transdermal patch - weekly What is this medicine? ESTRADIOL; LEVONORGESTREL (es tra DYE ole; LEE voh nor jes trel) is used as hormone replacement in ... Memorial Health Care System: Drug Reference





Featured Reviews

Reviews Mefloquine

Lariam Drug Description LARIAM® (mefloquine hydrochloride) Tablets DRUG DESCRIPTION What are the possible side effects of mefloquine (Lariam)? In some cases, serious mental side effects have occurred in people taking mefloquine....
Read More  |  Review This
Reviews Mandol

Mandol Drug Description DRUG DESCRIPTION Mandol® (Cefamandole Nafate for Injection, USP) is a semisynthetic broad-spectrum cephalosporin antibiotic for parenteral administration. It is 5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic...
Read More  |  Review This
Reviews Triamcinolone Cream

Triamcinolone Cream Drug Description Triamcinolone Acetonide Cream USP, 0.1% DRUG DESCRIPTION What are the possible side effects of triamcinolone topical (Cinolar, Kenalog, Triderm)? Get emergency medical help if you have any...
Read More  |  Review This
Reviews Heparin Lock Flush Solution

Lok Pak Drug Description DRUG DESCRIPTION WARNING: NOT FOR USE IN NEWBORNS Heparin Lock Flush Solution, USP is a sterile, nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water...
Read More  |  Review This
Reviews Mirapex ER

Mirapex ER Drug Description MIRAPEX® ER™ (pramipexole dihydrochloride) Extended-Release Tablets DRUG DESCRIPTION MIRAPEX ER tablets contain pramipexole, a non-ergot dopamine agonist. The chemical name of pramipexole dihydrochloride...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....